Establishment Labs (NASDAQ:ESTA) Stock Rating Upgraded by Wall Street Zen

Key Points

• Establishment Labs (NASDAQ: ESTA) has been upgraded from a "sell" to a "hold" rating by analysts at Wall Street Zen.
• The company's stock has a consensus rating of "Moderate Buy" with a target price of $56.50, with several analysts setting price targets ranging from $47.00 to $70.00.
• Establishment Labs reported a revenue of $51.30 million for the last quarter, marking a 16.1% increase year-over-year, but missed earnings expectations with an EPS of ($0.57).

Establishment Labs (NASDAQ:ESTA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Several other equities analysts also recently weighed in on ESTA. Mizuho increased their price target on shares of Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Needham & Company LLC reiterated a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research report on Friday, June 13th. Citigroup raised their price objective on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a report on Wednesday, July 9th. Finally, Canaccord Genuity Group began coverage on Establishment Labs in a research note on Wednesday, August 20th. They issued a "buy" rating and a $60.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Trading Up 1.8%

Shares of ESTA traded up $0.75 during trading hours on Friday, reaching $42.36. 33,603 shares of the company traded hands, compared to its average volume of 495,017. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -13.92 and a beta of 0.85. Establishment Labs has a 12-month low of $26.56 and a 12-month high of $50.85. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. The stock's fifty day moving average price is $40.16 and its 200 day moving average price is $37.83.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business's revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock worth $1,105,000 after acquiring an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its holdings in Establishment Labs by 5.2% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company's stock worth $257,000 after buying an additional 300 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Establishment Labs by 0.4% in the 1st quarter. Raymond James Financial Inc. now owns 119,752 shares of the company's stock worth $4,886,000 after purchasing an additional 491 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Establishment Labs by 1.3% in the 1st quarter. Swiss National Bank now owns 39,000 shares of the company's stock worth $1,591,000 after purchasing an additional 500 shares during the last quarter. Finally, CWM LLC increased its position in Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company's stock valued at $93,000 after acquiring an additional 686 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.